Conference Coverage

Intranasal naloxone promising for type 1 hypoglycemia

Publish date: July 17, 2018

 

REPORTING FROM ADA 2018

The study subjects were men, 43 years old, on average, with a mean body mass index of 26 kg/m2.

The investigators didn’t have any disclosures, and there was no industry funding for the work.

SOURCE: Aleksic S et al. ADA 2018, Abstract 10-LB.

Pages

Recommended Reading

High-bleeding-risk AF patients cut stroke risk with Amplatzer Amulet
MDedge Internal Medicine
Diabetes risk may rise with work hours
MDedge Internal Medicine
Study questions canagliflozin amputation risk, but concerns remain
MDedge Internal Medicine
High risk of low glucose? Hospital alerts promise a crucial heads-up
MDedge Internal Medicine
CANVAS program analysis: Canagliflozin benefits patients with T2DM and poor kidney function
MDedge Internal Medicine
Chronic kidney disease is 40% more common in T2DM than T1DM
MDedge Internal Medicine
CANVAS data: Canagliflozin generally well tolerated up to 6.5 years
MDedge Internal Medicine
Fluoroquinolones can cause fatal hypoglycemia, FDA warns
MDedge Internal Medicine
Meet the rare diabetes diagnosis that thrills patients
MDedge Internal Medicine
Special care advised for HIV-infected patients with diabetes
MDedge Internal Medicine